+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024 - Product Image

Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

  • ID: 4895824
  • Report
  • December 2019
  • Region: Global
  • 151 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
Global Conjugate Vaccines Market: About this market
The conjugate vaccines market analysis considers sales from the multivalent conjugate vaccine and monovalent conjugate vaccine types. Our study also finds the sales of conjugate vaccines in Asia, Europe, North America, and ROW. In 2019, the multivalent conjugate vaccine segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases will play a significant role in the multivalent conjugate vaccine segment to maintain its market position. Also, our global conjugate vaccines market report looks at factors such as increased funding for vaccine development, awareness about immunization programs and access to vaccines, and approval and regulatory incentives for conjugated vaccines. However, high costs associated with vaccine research, development, and manufacturing, safety concerns associated with conjugate vaccines, and challenges in development and global implementation of conjugate vaccines hamper the growth of the conjugate vaccines industry over the forecast period.

Global Conjugate Vaccines Market: Overview

Increasing awareness about immunization programs and access to vaccines
Initiatives aimed at increasing the awareness about well recognized and successful public health immunization programs are promoting the overall vaccine coverage around the globe. For instance, World Pneumonia Day is celebrated every year on November 12 to lower the incidence of pneumonia and reduce the resultant mortality rate. Similarly, other programs are focusing on improving drug delivery and diagnostics to address the health issues in low and middle-income countries. Such initiatives targeted towards boosting access to vaccines will drive the demand for conjugate vaccines. Conjugate vaccines are developed to immunize against a single antigen or two or more strains of the same microorganism. Thus, the promotion of immunization programs will lead to the expansion of the global conjugate vaccines market at a CAGR of over 9% during the forecast period.

Increasing efforts for stockpiling of conjugate vaccines
Governments are putting efforts to store vaccines in bulk to combat future emergency outbreaks of infectious diseases. For instance, The United Nations Children's Fund (UNICEF) works in collaboration with several public and private organizations to procure vaccines to combat future emergency outbreaks of infectious diseases. Furthermore, the International Coordinating Group (ICG) on Vaccine Provisions for Epidemic Meningitis Control also unites several public and private organizations to support emergency health programs and disease outbreak programs. The ongoing efforts in this area are expected to present significant growth opportunities for the existing vendors to meet the unmet demand for meningococcal conjugate vaccines, which will support the growth of the market during the forecast period.

Competitive Landscape
With the presence of a few major players, the global conjugate vaccines market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading conjugate vaccines manufacturers, that include Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Also, the conjugate vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Parent market
  • Market characteristics
  • Value Chain Analysis
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market Outlook
  • Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Multivalent conjugate vaccine - Market size and forecast 2019-2024
  • Monovalent conjugate vaccine - Market size and forecast 2019-2024
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing research activities for novel conjugate vaccine development
  • Emergence of strategies to improve conjugate vaccine manufacturing
  • Increasing efforts for stockpiling of conjugate vaccines
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Integrated Biotherapeutics Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key offerings
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Type - Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Multivalent conjugate vaccine - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Multivalent conjugate vaccine - Year-over-year growth 2020-2024 (%)
Exhibit 22: Monovalent conjugate vaccine - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Monovalent conjugate vaccine - Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. - Business segments
Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
Exhibit 53: Aurobindo Pharma Ltd. - Key customers
Exhibit 54: GlaxoSmithKline Plc - Vendor overview
Exhibit 55: GlaxoSmithKline Plc - Business segments
Exhibit 56: GlaxoSmithKline Plc - Organizational developments
Exhibit 57: GlaxoSmithKline Plc - Geographic focus
Exhibit 58: GlaxoSmithKline Plc - Segment focus
Exhibit 59: GlaxoSmithKline Plc - Key offerings
Exhibit 60: GlaxoSmithKline Plc - Key customers
Exhibit 61: Integrated Biotherapeutics Inc. - Vendor overview
Exhibit 62: Integrated Biotherapeutics Inc. - Business segments
Exhibit 63: Integrated Biotherapeutics Inc. - Key offerings
Exhibit 64: Integrated Biotherapeutics Inc. - Key customers
Exhibit 65: Merck & Co. Inc. - Vendor overview
Exhibit 66: Merck & Co. Inc. - Business segments
Exhibit 67: Merck & Co. Inc. - Organizational developments
Exhibit 68: Merck & Co. Inc. - Geographic focus
Exhibit 69: Merck & Co. Inc. - Segment focus
Exhibit 70: Merck & Co. Inc. - Key offerings
Exhibit 71: Merck & Co. Inc. - Key customers
Exhibit 72: Mitsubishi Tanabe Pharma Corp. - Vendor overview
Exhibit 73: Mitsubishi Tanabe Pharma Corp. - Business segments
Exhibit 74: Mitsubishi Tanabe Pharma Corp. - Organizational developments
Exhibit 75: Mitsubishi Tanabe Pharma Corp. - Geographic focus
Exhibit 76: Mitsubishi Tanabe Pharma Corp. - Key offerings
Exhibit 77: Mitsubishi Tanabe Pharma Corp. - Key customers
Exhibit 78: Pfenex Inc. - Vendor overview
Exhibit 79: Pfenex Inc. - Business segments
Exhibit 80: Pfenex Inc. - Organizational developments
Exhibit 81: Pfenex Inc. - Key offerings
Exhibit 82: Pfenex Inc. - Key customers
Exhibit 83: Pfizer Inc. - Vendor overview
Exhibit 84: Pfizer Inc. - Business segments
Exhibit 85: Pfizer Inc. - Organizational developments
Exhibit 86: Pfizer Inc. - Geographic focus
Exhibit 87: Pfizer Inc. - Segment focus
Exhibit 88: Pfizer Inc. - Key offerings
Exhibit 89: Pfizer Inc. - Key customers
Exhibit 90: Sanofi - Vendor overview
Exhibit 91: Sanofi - Business segments
Exhibit 92: Sanofi - Organizational developments
Exhibit 93: Sanofi - Geographic focus
Exhibit 94: Sanofi - Segment focus
Exhibit 95: Sanofi - Key offerings
Exhibit 96: Sanofi - Key customers
Exhibit 97: Serum Institute of India Pvt. Ltd. - Vendor overview
Exhibit 98: Serum Institute of India Pvt. Ltd. - Product segments
Exhibit 99: Serum Institute of India Pvt. Ltd. - Organizational developments
Exhibit 100: Serum Institute of India Pvt. Ltd. - Key offerings
Exhibit 101: Serum Institute of India Pvt. Ltd. - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Validation techniques employed for market sizing
Exhibit 109: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • MORE
The following companies as the key players in the global conjugate vaccines market: Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of strategies to improve conjugate vaccine manufacturing.”

According to the report, one of the major drivers for this market is the increasing awareness about immunization programs and access to vaccines.

Further, the report states that one of the major factors hindering the growth of this market is the challenges in the development and global implementation of conjugate vaccines.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Aurobindo Pharma Ltd.
  • GlaxoSmithKline Plc
  • Integrated Biotherapeutics Inc.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Pfenex Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll